PRediction Of Treatment Response to ECT in Depression and Cognitive Side effecTs (PROTECT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02562846|
Recruitment Status : Completed
First Posted : September 29, 2015
Last Update Posted : May 1, 2018
It has been convincingly demonstrated that electroconvulsive therapy (ECT) works better and sooner than antidepressants in the treatment of certain subtypes of depression. Given this effectiveness, it would be unfortunate not to give ECT to patients with good response chances as this could substantially shorten the length of a severe depressive episode. Instead of going through all possible psychopharmacological treatment steps, ECT could be proposed much earlier as a treatment option for those patients who might have good response chances. This would be a great advantage for the severely depressed patient, with a decreased disease-burden and hospitalization duration.
However, up to now, objective and reliable predictive factors for good ECT response have not yet been established. Clinical characteristics such as psychomotor retardation, psychotic features and age have often been used to predict the outcome of ECT, but there is too little evidence to consider these as strong predictive factors.
The current project is designed to allow better prediction of ECT-response. The investgators base their selection of predictors on clinical impression and previous research results. The predictive capacity of psychomotor functioning, psychotic symptoms and several biomarkers will be investigated. With these clinical and biological patient and depression characteristics, the investigators aim to develop a decision making tool that will allow a more accurate indication of ECT.
The investigators also investigate ways to predict whether or not a patient will have a good response when treatment has already started, based on an early improvement of psychomotor functioning.
Another subject of great importance is predicting and preventing side-effects. When patients at risk for lasting cognitive side-effects can be identified early in the treatment course, treatment can be adjusted to prevent persistence of memory problems. Therefore, the second part of the study focuses on identifying people at risk for cognitive side effects early in the treatment course.
|Condition or disease||Intervention/treatment|
|Depression||Other: Psychological testing and biological sample collection|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||74 participants|
|Target Follow-Up Duration:||9 Months|
|Official Title:||Prediction of ECT Treatment Response in Depression and Early Detection of ECT-related Memory Problems|
|Study Start Date :||June 2015|
|Actual Primary Completion Date :||September 30, 2017|
|Actual Study Completion Date :||February 28, 2018|
Depressive patients receiving electroconvulsive therapy.
Other: Psychological testing and biological sample collection
For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
- Change in depression severity as measured by the Hamilton Depression Rating Scale (HDRS) [ Time Frame: Baseline measurement before the first electroshock, compared with final HDRS score measured after the last electroshock of the acute ECT course. The duration between the measurement before and after ECT will be between 3-9 weeks. ]The HDRS is one of the most commonly used instruments for assessing depression. It is a valid and reliable clinician-rated measure that has been used extensively in clinical research and in clinical practice for assessment of the severity of depression, changes in its severity over time and efficacy of treatment.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02562846
|Duffel, Antwerp, Belgium, 2570|
|Study Director:||Bernard Sabbe, MD, prof.||Duffel Psychiatric Hospital|